CASI Pharmaceuticals Inc (NASDAQ:CASI) Director Wei-Wu He purchased 3,086,419 shares of CASI Pharmaceuticals stock in a transaction on Monday, March 19th. The stock was bought at an average price of $3.24 per share, for a total transaction of $9,999,997.56. Following the transaction, the director now directly owns 847,527 shares in the company, valued at approximately $2,745,987.48. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

Shares of CASI Pharmaceuticals stock traded up $0.15 during trading on Thursday, hitting $3.99. The company had a trading volume of 403,189 shares, compared to its average volume of 230,861. CASI Pharmaceuticals Inc has a 52 week low of $0.91 and a 52 week high of $4.84.

How to Become a New Pot Stock Millionaire

Institutional investors have recently made changes to their positions in the stock. Millennium Management LLC bought a new stake in shares of CASI Pharmaceuticals during the 4th quarter valued at about $137,000. Perceptive Advisors LLC bought a new stake in shares of CASI Pharmaceuticals during the 4th quarter valued at about $272,000. Renaissance Technologies LLC boosted its position in shares of CASI Pharmaceuticals by 33.4% during the 4th quarter. Renaissance Technologies LLC now owns 150,600 shares of the biotechnology company’s stock valued at $489,000 after purchasing an additional 37,700 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of CASI Pharmaceuticals by 488.7% during the 4th quarter. Geode Capital Management LLC now owns 225,578 shares of the biotechnology company’s stock valued at $733,000 after purchasing an additional 187,263 shares in the last quarter. Finally, BlackRock Inc. boosted its position in shares of CASI Pharmaceuticals by 32.6% during the 4th quarter. BlackRock Inc. now owns 386,090 shares of the biotechnology company’s stock valued at $1,254,000 after purchasing an additional 94,984 shares in the last quarter. Institutional investors own 5.11% of the company’s stock.

A number of equities research analysts have commented on CASI shares. BidaskClub lowered CASI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 14th. HC Wainwright reiterated a “buy” rating and issued a $4.50 price target on shares of CASI Pharmaceuticals in a research report on Monday, January 29th. Finally, ValuEngine upgraded CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday.

WARNING: “Insider Buying: CASI Pharmaceuticals Inc (CASI) Director Buys 3,086,419 Shares of Stock” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/insider-buying-casi-pharmaceuticals-inc-casi-director-buys-3086419-shares-of-stock/1957450.html.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.